Aesha Patel, DO

JACC STATE-OF-THE-ART REVIEW: do you have problems understanding all the new drugs to lower triglycerides and remnant cholesterol: lipid and side effects, target populations, approved or not by FDA+EMA? Ask Tybjærg Nordestgaard et al explain the details authors.elsevier.com/a/1l4pB2d9GI27…

🆕 #ACCEd Tackles hs-CRP’s Role in #CVD Check out the infographic 👇 which details the role of hs-CRP and influencing factors, along with materials on hs-CRP codes, recommendations, approaches, and further research. Explore the course: bit.ly/4iXhusn

New @ASPCardio Clinical Practice Statement🫀: Framework to improve cardiometabolic care for South Asians—individual to population level. ow.ly/glCT50VGq9Y @pnatarajanmd @jaideeppatelmd @dranandrohatgi @DrMarthaGulati @CiccaroneCenter #SouthAsianHealth #HeartHealth #ASPC

C-reactive protein (CRP) is a marker of inflammation and can help predict #heartdisease risk 📄 Help your patients understand CRP, inflammation and how it affects the heart with #CardioSmart’s latest infographic. Learn more: bit.ly/3Euhems

Palliative care in advanced CVD is essential to enhance quality of life, extending beyond end-of-life care to encompass the entire disease course. ✍🏼 @GravenLucinda @DeanLisaKitko @AbshireMartha @kofi_larry @Angie_Durante89 @LorraineEvang12 @FiedlerAmy @AL_CardiacRN

#CardioNuggets The Reynolds Risk Score refines 10-year CV risk—especially in women: ✅ Uses: Age, SBP, TC, HDL, hs-CRP, smoking, family hx 🔍 More accurate than Framingham for women Ideal for primary prevention decisions. #CardioTwitter #Prevention #Lipids

CVD is the most common cause of death for people with kidney failure. CKM syndrome is defined as a health disorder caused by the connections among obesity, diabetes, chronic kidney disease & CVD. 📷 Algorithm for managing patients with CKM syndrome Stage 4

ACC’s #CardioSmart recently launched a 🆕 app, CardioSmart360, designed to support treatment discussions between patients and their health care team. Find out more and download the new CardioSmart360 app for free! ➡️ bit.ly/43Vol1p #CardioX

Time to rethink how we monitor and manage silent atrial fibrillation. New meta-analysis sheds light on symptomatic vs. asymptomatic atrial fibrillation. Raed more in#EHJ. doi.org/10.1093/eurhea… #cardiotwitter @ESC_Journals @escardio

So grateful and honored to be co-chief resident with @aeshp_17! Learning so much at the Alliance for Academic Internal Medicine Conference! #chiefresidents #MedicalInnovation @uabmedicine #womeninSTEM #internalmedicine

For Lp(a), key therapeutic question remains: will lowering of Lp(a) reduce risk for cardiovascular events? Four subquestions: 1. how much Lp(a) lowering do you need [magnitude of Lp(a) lowering] 2. for how long [duration of treatment required] 3. in which patients [threshold of baseline Lp(a) level] 4. will lead to how much MACE reduction [magnitude of risk reduction] ? These questions should be answered collectively after the execution of three CVOT over next few years: 1. pelacarsen (HORIZON trial) 2. olpasiran (OCEAN trial) 3. lepodisiran (ACCLAIM trial)

It was a privilege to present 3 posters at #ACC25. Thank you Chicago for having me and @ACCinTouch for the opportunity. Shout-out to my co- researches @aeshp_17 @CMotley1 @iAlinasehar. And thank you to my mentors @DrDudenbostel and Dr. Urvish Patel for your continued guidance.

Extremely grateful for the opportunity to present and experience #ACC25 representing UAB Huntsville with the best! Thank you for your encouragement and support @DrDudenbostel @CMotley1 @sbag_in @pruthap287

DYK that 1 in 5 adults have an Lp(a) level that is too high. Use #CardioSmart’s Lp(a) Infographic to help patients understand this condition and how it might affect their heart. bit.ly/3RxBF4F #Cholesterol #ACC25

Limiting fluid intake may have no benefit for patients with #HeartFailure, according to findings from the FRESH-UP study presented during a Late-Breaking Clinical Trial session at #ACC25. Check out the key findings ➡️ bit.ly/3DYGHEl

Loved representing @uabmedicine Huntsville @ACCinTouch . Thank you @DrDudenbostel for the support. #ACC25 #Cardiology

Educate your patients about CRP, inflammation and how it affects the heart with #CardioSmart’s latest infographic: bit.ly/4hQ3ujt #ACC25

First day at #ACC25, here are the results of 10 trials presented today. I counted 3 NEJM, 1 Lancet, and 1 JAMA. WARRIOR: Intensive medical therapy did not reduce major CV events at five years in women with suspected INOCA. STRIDE: Semaglutide improved walking distance, symptoms, and quality of life in PAD with diabetes. API-CAT: Low-dose apixaban was noninferior to full-dose for preventing VTE recurrence in cancer patients. RIVAWAR: Rivaroxaban was as effective and safe as warfarin for post-MI LV thrombus resolution at three months. FARES-II: Four-factor PCC was superior to frozen plasma for bleeding control in cardiac surgery. REVERSE-IT: Bentracimab reversed ticagrelor’s antiplatelet effects in urgent surgery or major bleeding. HOST-BR: Three-month DAPT reduced adverse events without more bleeding vs. one-month in high-bleeding-risk patients post-stent. SOUL: Oral semaglutide reduced MACE by 14% over four years with no safety concerns. ADVANCE-HTN: Lorundrostat significantly lowered systolic BP at 12 weeks in uncontrolled hypertension. DAPA-TAVI: Dapagliflozin reduced mortality and heart failure worsening post-TAVI vs. standard care.

SOUL Results presented at #ACC25

Poor dietary habits are a major risk factor for #CVD. Plant-based, Mediterranean & DASH diets have all demonstrated clear cardioprotective benefits in primary & secondary prevention. More on heart-healthy eating ➡️ bit.ly/3FnnI6B #NationalNutritionMonth #CardioSmart